Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samir Parekh

Showing results (61-70 of 162) with videos related to

Pageof 17
Sort By:
American Journal of Hematology|October 6, 2022
Trial designs and endpoints for immune therapies in multiple myelomaGuido Lancman, Erin Moshier, Hearn Jay Cho, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2021
Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple MyelomaTarek H Mouhieddine, Julia Hieulle, Erin Moshier, et al.
Journal of Vascular and Interventional Radiology : JVIR|July 27, 2010
The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinomaRenumathy Dhanasekaran, Vinit Khanna, David A Kooby, et al.
Haematologica|July 2, 2026
Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myelomaTarek H Mouhieddine, Junia Vieira Dos Santos, Harshita Sehgal, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2013
Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemiaMeir Wetzler, Debora A Thomas, Eunice S Wang, et al.
Oncotarget|March 6, 2020
MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21<sup>Cip1</sup>Anna Huo-Chang Mei, Kaity Tung, Jessie Han, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 15, 2021
Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple MyelomaGuido Lancman, Katleen Lozada, Nida Athar, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 5, 2021
The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple MyelomaAnthony D Nehlsen, Kunal K Sindhu, Erin Moshier, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 15, 2020
Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current TherapiesSiyang Leng, Erin Moshier, Douglas Tremblay, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 18, 2021
Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple MyelomaAjai Chari, Erika Florendo, Ines Stefania Mancia, et al.
Pageof 17

Showing results (61-70 of 162) with videos related to

Sort By:
Pageof 17
American Journal of Hematology|October 6, 2022
Trial designs and endpoints for immune therapies in multiple myelomaGuido Lancman, Erin Moshier, Hearn Jay Cho, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 21, 2021
Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple MyelomaTarek H Mouhieddine, Julia Hieulle, Erin Moshier, et al.
Journal of Vascular and Interventional Radiology : JVIR|July 27, 2010
The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinomaRenumathy Dhanasekaran, Vinit Khanna, David A Kooby, et al.
Haematologica|July 2, 2026
Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myelomaTarek H Mouhieddine, Junia Vieira Dos Santos, Harshita Sehgal, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2013
Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemiaMeir Wetzler, Debora A Thomas, Eunice S Wang, et al.
Oncotarget|March 6, 2020
MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21<sup>Cip1</sup>Anna Huo-Chang Mei, Kaity Tung, Jessie Han, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 15, 2021
Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple MyelomaGuido Lancman, Katleen Lozada, Nida Athar, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 5, 2021
The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple MyelomaAnthony D Nehlsen, Kunal K Sindhu, Erin Moshier, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 15, 2020
Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current TherapiesSiyang Leng, Erin Moshier, Douglas Tremblay, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 18, 2021
Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple MyelomaAjai Chari, Erika Florendo, Ines Stefania Mancia, et al.
Pageof 17